Health Condition 1: null- Diagnosed and confirmed as Empyema thoracis stage-II
Conditions
Interventions
Intervention1: 1.Chest Tube (ICD)
2.Chest Tube with Fibrinolytics 3.VATS: 1.Comparison of VATS with chest tube drainage in terms of various variables for treatment of Empyema Thoracic Stage-II.
2. Co
Sponsors
AIIMS Rishikesh
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients adults (more than 18 years) diagnosed as Empyema thoracic in fibrinopurulent stage-II. 2. Thoracic empyema will be defined as pleural effusion that fulfilled at least one of following criteria: (a) Presence of frank pus on pleural aspiration. (b) Presence of organism on pleural fluid culture. (c) Positive pleural fluid Gram stain. 3. Tuberculous empyema will be defined as empyema with one of following: (a) Pleural fluid smear positive for acid fast bacilli (AFB). (b) Sputum positive for AFB and radiological lesions consistent with active parenchymal tuberculosis on chest x-ray/CT scan of thorax . (c) CBNAT Study 4. Probable tuberculous empyema will be defined as empyema with radiological evidence of active pulmonary tuberculosis on chest x-ray/CT scan of thorax with sputum negative for AFB.
Exclusion criteria
Exclusion criteria: 1. Age less than 18 years. 2. Empyema secondary to penetrating chest trauma. 3. Empyema secondary to or following any thoracic surgical procedure. 4. Empyema due to carcinoma or terminally ill patients. 5. Patients not fit for surgery/intervention. 6. Patients with co morbid diseases like cardiac disorders and immunosuppression. 7. Unwilling/No consent for participation in study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To cure from Empyema 1. expansion of Lung 2. No residual Infection in Pleural cavityTimepoint: To cure from Empyema - AFTER 1 Month of starting treatment 1. expansion of Lung 2. No residual Infection in Pleural cavity | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Post procedural air-leak duration 2. Duration of chest tube in situ 3. Hospital stay duration 4. Time to return to work 5. Treatment failure / re-operation 6. Mortality 7. Other complications Timepoint: At the End of Trial. Each patient data will be analyzed. | — |
Countries
India
Contacts
Public ContactDr Anshuman Darbari
AIIMS, RISHIKESH
Outcome results
None listed